Urinary Diversion Tapa dura - 2017

Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University and was then recruited to USC Institute of Urology in 2010 as Director of Urologic Oncology. He is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director.

Dr. Daneshmand's main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience with radical cystectomy and continent urinary diversion. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following continent urinary diversion. He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy and his protocol has significantly reduced hospital stay while improving the patient experience. He serves on the editorial board of the Bladder Cancer Journal, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the American Urological Society/ Society of Urologic Oncology Guideline Committee on non-muscle invasive bladder cancer. He is a member of Alpha Omega Alpha medical honor society, and has been designated one of the "America's Top Cancer Doctors" for numerous consecutive years. He is an active member of the Society of Urologic Oncology, has presented over 300 abstracts at scientific meetings and has authored over 200 peer-reviewed articles, reviews, and chapters. He is a reviewer for numerous urology journals.